ARTICLE
5 September 2018

CMS Allows Medicare Part D Indication-Based Formulary Design

HK
Holland & Knight

Contributor

Holland & Knight is a global law firm with nearly 2,000 lawyers in offices throughout the world. Our attorneys provide representation in litigation, business, real estate, healthcare and governmental law. Interdisciplinary practice groups and industry-based teams provide clients with access to attorneys throughout the firm, regardless of location.
The Centers for Medicare & Medicaid Services (CMS) has just announced a significant shift in Medicare Part D formulary design to allow Part D sponsors to customize their formularies...
United States Food, Drugs, Healthcare, Life Sciences

Melissa A Wong is Associate in Holland & Knight's Boston office

The Centers for Medicare & Medicaid Services (CMS) has just announced a significant shift in Medicare Part D formulary design to allow Part D sponsors to customize their formularies based not just on the drug, but also based on the drug's indication, or the patient condition that the drug is intended to treat. Currently, drugs that are included on a Part D plan's formulary must be covered for all FDA-approved indications for that drug, except those indications that are statutorily excluded under Part D. While Part D sponsors are permitted to use separate prior authorization approval criteria specific to a drug's indication, this new policy goes a step further to incorporate drug indications directly into formularies themselves.

CMS will allow indication-based formulary design beginning with the 2020 plan year and all existing Part D formulary requirements will still apply once the change goes into effect. For instance, if a Part D sponsor limits formulary coverage of a drug to certain indications, it must still include a therapeutically similar, on-formulary drug for that non-formulary indication. Sponsors must also continue to process formulary exception requests made by beneficiaries and providers for excluded indications of on-formulary drugs.

While this change remains in the not-too-distant future, Part D sponsors, pharmacy benefit managers (PBMs) and pharmaceutical manufacturers will soon be negotiating formulary inclusion and pricing well in advance of the 2020 plan year. In addition, Part D sponsors and PBMs must begin planning for operational changes as well, including possible impacts to the Pharmacy & Therapeutics Committee evaluation process for approving formularies, an expected increase in the volume and complexity of formulary exception requests and a redesign of Medicare Plan Finder and other beneficiary notices and materials.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More